Outcome | Best-fitted lag period in years (90% CI)† | Median TSLE in years among cases (range) | HR at 50 ppm-years (95% CI) |
MN urinary | 34 (19 to 39) | 29.9 (0.3 to 49.5) | 2.39 (1.92 to 3.25) |
MN kidney | 33 (<1 to >40) | 27.6 (5.9 to 41.1) | 2.39 (1.92 to 3.83) |
MN bladder | 37 (35 to 39) | 32.1 (0.3 to 49.5) | 6.20 (3.93 to 11.83) |
MN lymphatic and haematopoietic | 37 (33 to 39) | 34.1 (8.4 to 52.0) | 4.32 (3.00 to 6.56) |
Non-Hodgkin's lymphoma | 40<1 to >40 | 32.2 (12.9 to 52.0) | 0.01 (NC to 3.52) |
Multiple myeloma | 40 (17 to >40) | 38.5 (8.4 to 42.2) | 34 (14.08 to 96.94) |
Leukaemia | 37 (20 to 39) | 36.4 (19.1 to 51.1) | 4.10 (2.88 to 7.29) |
Myeloid leukaemia | 37 (20 to 39) | 34.1 (19.1 to 51.1) | 11.67 (6.31 to 30.76) |
*RCS models matched on attained age, sex, race (Caucasian, other), birth cohort (within 5 years), and employment duration (<1 year, ≥1 year) and using the best-fitted lag.
†Lags were examined using a grid search of a range of lags from 2 to 40 years in 1-year increments.
MN, malignant neoplasm; NC, not calculable; RCS, restricted cubic spline.